FUNDAMENTAL & CLINICAL PHARMACOLOGY

Scope & Guideline

Advancing pharmacological knowledge for better health outcomes.

Introduction

Welcome to the FUNDAMENTAL & CLINICAL PHARMACOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of FUNDAMENTAL & CLINICAL PHARMACOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN0767-3981
PublisherWILEY
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1987 to 2024
AbbreviationFUND CLIN PHARMACOL / Fundam. Clin. Pharmacol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address111 RIVER ST, HOBOKEN 07030-5774, NJ

Aims and Scopes

FUNDAMENTAL & CLINICAL PHARMACOLOGY aims to bridge the gap between fundamental pharmacological research and clinical applications. The journal focuses on the pharmacological aspects of drug therapy, including mechanisms of action, therapeutic efficacy, and safety profiles in various populations.
  1. Pharmacological Mechanisms and Drug Actions:
    This area encompasses studies that investigate the biochemical and molecular mechanisms through which drugs exert their effects, including receptor interactions, signaling pathways, and pharmacodynamics.
  2. Clinical Pharmacology and Therapeutics:
    Research focusing on the clinical implications of pharmacotherapy, including the efficacy and safety of drugs in specific patient populations, therapeutic drug monitoring, and the optimization of dosing regimens.
  3. Pharmacovigilance and Drug Safety:
    The journal emphasizes the importance of pharmacovigilance, reporting adverse drug reactions, and monitoring drug safety in clinical practice, particularly in vulnerable populations.
  4. Pharmacogenetics and Personalization of Therapy:
    Studies exploring genetic factors influencing drug metabolism and response, aiming to tailor pharmacotherapy to individual patient profiles for better outcomes.
  5. Innovative Drug Development and Therapeutic Strategies:
    Research on new therapeutic agents, drug repurposing, and innovative approaches to enhance treatment efficacy and minimize side effects.
  6. Epidemiology and Public Health:
    This scope includes studies assessing drug utilization patterns, the impact of drug policies on public health, and the epidemiological trends of drug-related issues.
Emerging trends in FUNDAMENTAL & CLINICAL PHARMACOLOGY reflect a growing interest in personalized medicine, advanced therapeutic strategies, and the integration of pharmacogenomics into clinical practice. These areas are increasingly relevant as the field evolves to address contemporary health challenges.
  1. Personalized Medicine and Pharmacogenomics:
    There is a marked increase in research focusing on tailoring pharmacotherapy based on genetic profiles, emphasizing the need for personalized approaches to enhance drug efficacy and minimize adverse effects.
  2. Real-World Evidence and Pragmatic Trials:
    Growing interest in studies that evaluate drug effectiveness and safety in real-world settings, moving beyond controlled clinical trials to understand how drugs perform in diverse patient populations.
  3. Immunotherapy and Biologics:
    Research into immunotherapy, particularly the use of monoclonal antibodies and checkpoint inhibitors, is expanding, reflecting an increasing recognition of their potential in treating various conditions, including cancer.
  4. Digital Health and Pharmacovigilance Technologies:
    Emerging technologies for monitoring drug safety and efficacy, including mobile health applications and artificial intelligence, are gaining traction as tools for enhancing pharmacovigilance.
  5. Neuropharmacology and Mental Health:
    There is a rising focus on the pharmacological management of mental health disorders, exploring novel therapeutic agents and their mechanisms of action in neurological contexts.

Declining or Waning

While FUNDAMENTAL & CLINICAL PHARMACOLOGY continues to expand its research frontiers, certain themes have become less prominent in recent years. This decline may reflect shifting research priorities or advancements in other areas of pharmacology.
  1. Traditional Herbal Medicine:
    Research on herbal medicines and their pharmacological effects has seen a decline, possibly due to the increasing focus on synthetic drugs and biologics that provide more consistent results in clinical settings.
  2. Basic Toxicology Studies:
    While toxicology remains a crucial area, the focus on basic toxicological mechanisms has waned in favor of more applied studies that directly address clinical implications and drug safety.
  3. Animal Models of Drug Action:
    Although animal studies are still important, there has been a shift towards human-based research and clinical trials, with less emphasis on preclinical animal models compared to previous years.
  4. Drug Formulation Studies:
    Research focused solely on the formulation aspects of drug development has decreased, as the field moves towards integrated approaches that combine formulation with clinical efficacy and safety assessments.

Similar Journals

Clinical Pharmacology-Advances and Applications

Exploring New Frontiers in Pharmacological Science
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1438Frequency: 1 issue/year

Clinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.

PHARMAZIE

Transforming pharmaceutical practices through research.
Publisher: AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBHISSN: 0031-7144Frequency: 12 issues/year

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Illuminating the path to ocular health advancements.
Publisher: MARY ANN LIEBERT, INCISSN: 1080-7683Frequency: 10 issues/year

JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, published by Mary Ann Liebert, Inc, stands at the forefront of research in the realms of ophthalmology and pharmacology. Established in 1985 and converging until 2024, this esteemed journal is dedicated to advancing the understanding of ocular pharmacology, drug therapies, and therapeutic approaches in the treatment of eye diseases. With an impressive impact factor and categorized in the Q2 quartile for both Ophthalmology and Medical Pharmacology, it showcases pivotal research in the field, reflecting its rank of #31 among 137 in Ophthalmology and #109 among 272 in Medical Pharmacology per Scopus metrics. Although it follows a subscription-based model, the journal provides critical insights and empirical studies that foster innovation and collaboration for researchers, professionals, and students alike in the pursuit of improving ocular health.

Advances in Pharmacology and Pharmacy

Advancing the Frontiers of Pharmacological Research
Publisher: HORIZON RESEARCH PUBLISHINGISSN: 2332-0036Frequency: 3 issues/year

Advances in Pharmacology and Pharmacy is a pioneering journal devoted to the dissemination of cutting-edge research in the fields of pharmacology and pharmaceutical sciences. Published by Horizon Research Publishing, this peer-reviewed journal boasts a commitment to advancing knowledge and innovation, making it an essential resource for researchers, industry professionals, and students alike. With an ISSN of 2332-0036 and an E-ISSN of 2332-0044, it provides a platform for high-quality research articles that explore new therapeutic approaches, drug development strategies, and the regulatory aspects of pharmaceutical science. Although currently lacking a formal impact factor, the journal's emphasis on open access ensures that articles are widely available, promoting the sharing of valuable insights and collaborative efforts in the scientific community. Located at 506 N Garfield Ave, Ste 210, Alhambra, CA 91801, the journal welcomes contributions from diverse areas within pharmacology and pharmacy, reinforcing its significance as a vital resource in the ever-evolving landscape of pharmaceutical research.

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Championing High-Impact Research in Clinical Pharmacology
Publisher: WILEYISSN: 0306-5251Frequency: 12 issues/year

British Journal of Clinical Pharmacology, published by Wiley, is a premier peer-reviewed journal that has been at the forefront of pharmacology research since its inception in 1974. Renowned for its high academic rigor, it stands out with an impressive impact factor that places it in the Q1 quartile within both the general pharmacology and medical pharmacology categories. With a Scopus ranking reflecting its esteemed status—ranked #68 out of 272 in medical pharmacology and #109 out of 313 in pharmacology, toxicology, and pharmaceutics—the journal serves as a critical resource for researchers, clinicians, and students who are keen to explore innovations and advancements in drug therapy. The journal's scope encompasses a wide array of topics, including clinical trials, drug safety, and pharmacokinetics, making it an essential platform for disseminating cutting-edge pharmacological findings. Although it does not offer open access, the stringent selection of articles ensures that only the highest-quality research is published, further contributing to the ongoing discourse in clinical pharmacology.

Journal of Pharmacological Sciences

Innovating drug development through impactful science.
Publisher: JAPANESE PHARMACOLOGICAL SOCISSN: 1347-8613Frequency: 12 issues/year

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

BIOLOGICAL & PHARMACEUTICAL BULLETIN

Fostering Excellence in Biomedical and Pharmaceutical Discourse
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0918-6158Frequency: 12 issues/year

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

DRUGS & THERAPY PERSPECTIVES

Empowering Researchers and Practitioners in Drug Therapy
Publisher: SPRINGERNATUREISSN: 1172-0360Frequency: 12 issues/year

DRUGS & THERAPY PERSPECTIVES is an esteemed journal published by SpringerNature, dedicated to advancing knowledge in the field of pharmacology and therapeutic studies. With an ISSN of 1172-0360 and an E-ISSN of 1179-1977, this journal has been providing valuable insights since its inception in 1993 and continues to publish until 2024. Ranked in the Q3 category for Pharmacology (medical) and positioned within the 25th percentile according to Scopus rankings, it serves as a vital resource for researchers, practitioners, and students alike. Although it is not an open-access journal, it offers a comprehensive platform for innovative research, clinical practices, and evolving therapeutic strategies, reflecting the critical developments in drug therapy landscape. With its strategic emphasis on bridging academic studies and clinical applications, DRUGS & THERAPY PERSPECTIVES remains essential for those committed to enhancing drug efficacy and patient outcomes in the ever-evolving medical field.

PHARMACOTHERAPY

Transforming Pharmacological Science for Tomorrow
Publisher: WILEYISSN: 0277-0008Frequency: 12 issues/year

PHARMACOTHERAPY, an esteemed journal published by WILEY, stands as a pivotal resource within the field of medical pharmacology. With its ISSN 0277-0008 and E-ISSN 1875-9114, this journal has been at the forefront of pharmacological research since its inception in 1981. Renowned for its rigorous peer-review process and impactful contributions, it currently holds a prestigious Q1 quartile ranking in the pharmacology category, underscoring its significance as a leading publication in the field. It ranks #40 out of 272 journals in Scopus, placing it in the top 15% percentile of its category. While not an open-access publication, PHARMACOTHERAPY remains committed to advancing knowledge and understanding in pharmacological sciences, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to improving therapeutic outcomes and drug utilization. Based in the United States, at 111 River St, Hoboken, NJ, the journal is poised to continue its impact through to 2024 and beyond, welcoming contributions that further the discourse in pharmacotherapy.

European Journal of Pharmacology

Fostering interdisciplinary collaboration in the realm of pharmacology.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.